|
BE640616A
(https=)
|
1962-12-19 |
|
|
|
|
US3492397A
(en)
|
1967-04-07 |
1970-01-27 |
Warner Lambert Pharmaceutical |
Sustained release dosage in the pellet form and process thereof
|
|
US4060598A
(en)
|
1967-06-28 |
1977-11-29 |
Boehringer Mannheim G.M.B.H. |
Tablets coated with aqueous resin dispersions
|
|
US3538214A
(en)
|
1969-04-22 |
1970-11-03 |
Merck & Co Inc |
Controlled release medicinal tablets
|
|
US4173626A
(en)
|
1978-12-11 |
1979-11-06 |
Merck & Co., Inc. |
Sustained release indomethacin
|
|
GB9404485D0
(en)
|
1994-03-09 |
1994-04-20 |
Cancer Res Campaign Tech |
Benzamide analogues
|
|
AT401651B
(de)
|
1994-06-14 |
1996-11-25 |
Biochemie Gmbh |
7-(2-(2-aminothiazol-4-yl)-2-(z)- hydroximinoacetamido)-3-n,n- dimethylcarbamoyloxymethyl-3-cephem-4-
|
|
EP0841924B1
(en)
|
1995-08-02 |
2002-10-02 |
Newcastle University Ventures Limited |
Benzimidazole compounds
|
|
CA2332279A1
(en)
|
1998-05-15 |
1999-11-25 |
Jia-He Li |
Carboxamide compounds, compositions, and methods for inhibiting parp activity
|
|
EP1124805B1
(de)
|
1998-10-30 |
2003-05-21 |
Lonza AG |
Verfahren zur herstellung von 4-[(2',5'-diamino-6'-halogenpyrimidin-4'-yl)amino]-cyclopent-2-enylmethanolen
|
|
IL142917A0
(en)
|
1998-11-03 |
2002-04-21 |
Basf Ag |
Substituted 2-phenylbenzimidazoles, the production thereof and their use
|
|
HRP20010451A2
(en)
|
1998-11-17 |
2003-04-30 |
Basf Ag |
2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof
|
|
TR200101498T2
(tr)
|
1998-11-27 |
2001-11-21 |
Basf Aktiengesellschaft |
İkameli benzimidazoller ve parp inhibitörleri olarak kullanımları
|
|
DE19918211A1
(de)
|
1999-04-22 |
2000-10-26 |
Basf Ag |
Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
|
|
DE19920936A1
(de)
|
1999-05-07 |
2000-11-09 |
Basf Ag |
Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
|
|
AU7314200A
(en)
|
1999-09-17 |
2001-04-24 |
Yamanouchi Pharmaceutical Co., Ltd. |
Benzimidazole derivatives
|
|
DE50112961D1
(de)
|
2000-02-01 |
2007-10-18 |
Abbott Gmbh & Co Kg |
Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
|
|
DE10022925A1
(de)
|
2000-05-11 |
2001-11-15 |
Basf Ag |
Substituierte Indole als PARP-Inhibitoren
|
|
JPWO2002068407A1
(ja)
|
2001-02-28 |
2004-06-24 |
山之内製薬株式会社 |
ベンゾイミダゾール化合物
|
|
JP2003005323A
(ja)
|
2001-06-20 |
2003-01-08 |
Konica Corp |
熱現像写真感光材料及び画像形成方法
|
|
WO2003007959A1
(en)
|
2001-07-16 |
2003-01-30 |
Fujisawa Pharmaceutical Co., Ltd. |
Quinoxaline derivatives which have parp inhibitory action
|
|
BR0212841A
(pt)
|
2001-09-26 |
2004-08-03 |
Pharmacia Italia Spa |
Derivado ativo de aminoindazole como inibidores de cinase, processo para sua preparação e composições farmacêuticas que os contém
|
|
WO2003062234A1
(en)
|
2002-01-23 |
2003-07-31 |
Yamanouchi Pharmaceutical Co., Ltd. |
Quinoxaline compounds
|
|
US20040034078A1
(en)
|
2002-06-14 |
2004-02-19 |
Agouron Pharmaceuticals, Inc. |
Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
|
|
JPWO2004014861A1
(ja)
|
2002-08-09 |
2005-12-02 |
杏林製薬株式会社 |
４−置換キノリン−８−カルボン酸アミド誘導体とその薬理上許容される付加塩
|
|
AU2003296405A1
(en)
|
2003-01-06 |
2004-08-10 |
Eli Lilly And Company |
Fused heterocyclic derivatives as ppar modulators
|
|
ATE411980T1
(de)
|
2003-07-21 |
2008-11-15 |
Smithkline Beecham Corp |
(2s,4s)-4-fluor-1-ä4-fluor-beta-(4-fluorphenyl) l-phenylalanylü-2-pyrrolidincarbonitril-p- toluolsulfonsäuresalz und wasserfreie kristalline formen davon
|
|
WO2005047290A2
(en)
|
2003-11-11 |
2005-05-26 |
Cellular Genomics Inc. |
Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
|
|
GB0327740D0
(en)
|
2003-11-28 |
2003-12-31 |
Glaxo Group Ltd |
Novel compounds
|
|
WO2005066136A1
(en)
|
2003-12-22 |
2005-07-21 |
Eli Lilly And Company |
Bicyclic derivatives as ppar modulators
|
|
ATE540936T1
(de)
|
2004-06-30 |
2012-01-15 |
Janssen Pharmaceutica Nv |
Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
|
|
PT1794163E
(pt)
|
2004-09-22 |
2010-03-01 |
Pfizer |
Método para a preparação de inibidores de poli(adpribose)- polimerases
|
|
EP1812439B2
(en)
|
2004-10-15 |
2017-12-06 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
JP3701964B1
(ja)
|
2005-03-08 |
2005-10-05 |
アステラス製薬株式会社 |
キヌクリジン誘導体の新規な塩
|
|
TWI375673B
(en)
|
2005-04-11 |
2012-11-01 |
Abbott Lab |
1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
|
|
US7728026B2
(en)
|
2005-04-11 |
2010-06-01 |
Abbott Laboratories, Inc. |
2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
|
|
JP5227796B2
(ja)
|
2005-09-29 |
2013-07-03 |
アボット・ラボラトリーズ |
２位においてフェニルによって置換された１ｈ−ベンズイミダゾール−４−カルボキサミドは強力なｐａｒｐ阻害薬である
|
|
JP5162465B2
(ja)
|
2005-11-15 |
2013-03-13 |
アボット・ラボラトリーズ |
置換１ｈ−ベンズイミダゾール−４−カルボキサミド類は強力なｐａｒｐ阻害薬である
|
|
CA2647545C
(en)
|
2006-04-03 |
2016-02-23 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
|
|
MX2008014004A
(es)
|
2006-05-02 |
2008-11-12 |
Abbott Lab |
1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes.
|
|
JP4611444B2
(ja)
|
2007-01-10 |
2011-01-12 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
|
|
US20090062268A1
(en)
|
2007-08-27 |
2009-03-05 |
Lead Therapeutics, Inc. |
Novel inhibitors of poly(adp-ribose)polymerase (parp)
|
|
KR101653548B1
(ko)
|
2008-01-08 |
2016-09-02 |
머크 샤프 앤드 돔 리미티드 |
2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염
|
|
WO2009099736A2
(en)
|
2008-02-06 |
2009-08-13 |
Lead Therapeutics, Inc. |
Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp)
|
|
EP2928473B1
(en)
|
2012-12-07 |
2017-06-28 |
Merck Sharp & Dohme Corp. |
Regioselective n-2 arylation of indazoles
|
|
SMT202100065T1
(it)
|
2013-05-02 |
2021-03-15 |
Anaptysbio Inc |
Anticorpi diretti contro la proteina della morte programmata (pd-1)
|
|
MA41463A
(fr)
|
2015-02-03 |
2017-12-12 |
Anaptysbio Inc |
Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
|
|
FI3277321T3
(fi)
|
2015-04-01 |
2024-10-31 |
Anaptysbio Inc |
T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
|
|
WO2017218365A1
(en)
|
2016-06-16 |
2017-12-21 |
Sunshine Lake Pharma Co., Ltd. |
Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
|
|
SG11201811564QA
(en)
|
2016-06-29 |
2019-01-30 |
Tesaro Inc |
Methods of treating ovarian cancer
|
|
WO2018018354A1
(zh)
|
2016-07-25 |
2018-02-01 |
刘文婷 |
超市智能结算购物车及其使用方法
|
|
CN106496187A
(zh)
*
|
2016-09-14 |
2017-03-15 |
陕西科技大学 |
一种制备PARP抑制剂Niraparib的合成方法
|
|
JP2019533458A
(ja)
|
2016-11-01 |
2019-11-21 |
アナプティスバイオ インコーポレイティッド |
プログラム死１（ｐｄ−１）に対する抗体
|
|
MX2019005116A
(es)
|
2016-11-01 |
2019-11-12 |
Anaptysbio Inc |
Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3).
|
|
CN108201537A
(zh)
|
2016-12-16 |
2018-06-26 |
苏州苏融生物医药有限公司 |
一种尼拉帕尼缓控释药物组合物及其用途
|
|
WO2018122168A1
(en)
|
2016-12-29 |
2018-07-05 |
Bayer Pharma Aktiengesellschaft |
Combinations of bub1 kinase and parp inhibitors
|
|
WO2018129553A1
(en)
|
2017-01-09 |
2018-07-12 |
Tesaro, Inc. |
Methods of treating cancer with anti-tim-3 antibodies
|
|
AU2018206481B2
(en)
|
2017-01-09 |
2025-02-27 |
Tesaro, Inc. |
Methods of treating cancer with anti-PD-1 antibodies
|
|
CN110944638A
(zh)
|
2017-03-27 |
2020-03-31 |
特沙诺有限公司 |
尼拉帕尼组合物
|
|
MA48475A
(fr)
|
2017-04-24 |
2020-03-04 |
Tesaro Inc |
Procédés de fabrication de niraparib
|
|
SG11201909395TA
(en)
|
2017-04-27 |
2019-11-28 |
Tesaro Inc |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
|
KR20200005662A
(ko)
|
2017-05-18 |
2020-01-15 |
테사로, 인코포레이티드 |
암을 치료하기 위한 조합 요법
|
|
CN108530425A
(zh)
|
2017-05-27 |
2018-09-14 |
广州科锐特生物科技有限公司 |
一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法
|
|
CN108203404A
(zh)
|
2018-03-02 |
2018-06-26 |
上海博邦医药科技有限公司 |
(r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法
|
|
JP2022504228A
(ja)
|
2018-10-03 |
2022-01-13 |
テサロ， インコーポレイテッド |
ニラパリブ遊離塩基の結晶形態
|